Sign In
Buy MDGL
$531.00
-5.70 (-1.06%)
At Close: Jul 13, 2026
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
08:00am, Monday, 13'th Jul 2026
Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmeti
3 Under-the-Radar Stocks to Buy and Hold
02:30pm, Friday, 10'th Jul 2026
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 06'th Jul 2026
CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH
02:27am, Thursday, 02'nd Jul 2026
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals AB (en adelante, "Ribo"), en colaboración con Madrigal
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
09:19pm, Wednesday, 01'st Jul 2026
SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 22'nd Jun 2026
CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
3 Under-the-Radar Stocks to Buy and Hold for a Decade
03:30am, Tuesday, 16'th Jun 2026
All three could become highly prominent biotech companies within 10 years.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:22pm, Wednesday, 10'th Jun 2026
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
12:35pm, Friday, 05'th Jun 2026
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 04'th Jun 2026
CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
08:00am, Wednesday, 03'rd Jun 2026
CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care
Madrigal Pharmaceuticals Could Become The Next Vertex
09:40pm, Tuesday, 02'nd Jun 2026
Madrigal Pharmaceuticals, Inc. is a high-risk/high-reward play, focused solely on MASH with its first-in-class drug Rezdiffra. Rezdiffra's initial U.S. TAM is expanding, with diagnosis rates and label
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
08:00am, Wednesday, 27'th May 2026
Growing body of clinical and real-world evidence supports the role of Rezdiffra ® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles associa
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st May 2026
CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associa
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra ® (resmetirom) Analysis of two-year data i
